A 52-year-old woman from Mumbai presents with a 4 cm hard, fixed mass in the upper outer quadrant of the right breast with skin dimpling and a positive Peau d'orange appearance. On examination, she has palpable ipsilateral axillary lymph nodes (approximately 2 cm, matted). Contralateral breast and axilla are normal. Mammography confirms a 4 cm lesion with skin thickening. Core needle biopsy shows invasive lobular carcinoma (ILC), ER/PR positive, HER2 negative. Staging CT chest/abdomen and bone scan reveal no distant metastases. Clinical diagnosis: T4b, N1, M0 (Stage IIIB). What is the most appropriate initial management strategy?

Explanation

## Clinical Staging and Assessment This patient has: - **T4b** (skin involvement: Peau d'orange, dimpling) - **N1** (ipsilateral axillary lymph nodes) - **M0** (no distant metastases) - **Stage IIIB** (locally advanced breast cancer) **Key Point:** Locally advanced breast cancer (stage III) is managed with a multimodal approach: **neoadjuvant chemotherapy → surgery → adjuvant therapy** [cite:Harrison 21e Ch 297]. ## Why Neoadjuvant Chemotherapy? ### Goals of Neoadjuvant Therapy | Goal | Benefit | |------|----------| | Downstaging | Reduces tumour volume; may convert inoperable to operable disease | | Margin achievement | Increases likelihood of R0 resection | | Systemic control | Treats micrometastatic disease early | | Prognostic assessment | Pathological complete response (pCR) is a strong prognostic indicator | | Breast conservation | May allow BCT in selected cases (though less common in ILC) | **High-Yield:** Neoadjuvant chemotherapy is the **standard of care for stage III breast cancer** before definitive surgery [cite:Robbins 10e Ch 22]. ### Typical Neoadjuvant Regimen **Mnemonic: "ACH" or "FAC" regimens** - **A**driamycin (doxorubicin) + **C**yclophosphamide + **H**erceptin (if HER2+) - **F**luorouracil + **A**driamycin + **C**yclophosphamide - Followed by taxane (paclitaxel or docetaxel) for additional benefit This patient (ER/PR+, HER2−) would typically receive anthracycline-based chemotherapy without HER2-targeted therapy. ## Post-Neoadjuvant Assessment After 3–4 cycles of neoadjuvant chemotherapy: 1. **Clinical reassessment** (physical exam, imaging) 2. **Imaging** (mammography, ultrasound, or MRI) to assess response 3. **Surgical planning** based on residual disease **Clinical Pearl:** Even if complete clinical response is achieved, surgery is still mandatory to remove the tumour bed and assess for pathological complete response (pCR). pCR is associated with improved disease-free and overall survival. ## Surgical Management After Neoadjuvant Therapy Most patients with stage IIIB disease will require: - **Modified radical mastectomy** with axillary lymph node dissection - Breast conservation is rarely feasible due to T4b status and diffuse involvement - Reconstruction may be considered after oncological clearance ## Adjuvant Therapy After Surgery - **Radiotherapy:** Chest wall and regional nodes (standard for stage III) - **Systemic therapy:** Continuation of chemotherapy (if incomplete) + hormonal therapy (tamoxifen or AI for ER/PR+ disease) **Warning:** Do NOT start with surgery alone in stage III disease — this omits the proven benefit of neoadjuvant chemotherapy and increases the risk of inadequate resection and early recurrence.